| Identification | Back Directory | [Name]
3-(trifluoromethyl)-6,7-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-8(5H)-one | [CAS]
877402-45-4 | [Synonyms]
Sitagliptin Impurity 114
3-(trifluoromethyl)-5H,6H,7H,8H-[1,2,4]triazolo[4,3-
a]pyrazin-8-one
3-(trifluoromethyl)-6,7-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-8(5H)-one
1,2,4-Triazolo[4,3-a]pyrazin-8(5H)-one, 6,7-dihydro-3-(trifluoromethyl)- | [Molecular Formula]
C6H5F3N4O | [MDL Number]
MFCD24609250 | [MOL File]
877402-45-4.mol | [Molecular Weight]
206.13 |
| Chemical Properties | Back Directory | [density ]
1.90±0.1 g/cm3(Predicted) | [solubility ]
DMSO (Slightly), Methanol (Slightly) | [form ]
Solid | [pka]
12.69±0.20(Predicted) | [color ]
Off-White to Light Grey |
| Hazard Information | Back Directory | [Uses]
3-(Trifluoromethyl)-6,7-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-8(5H)-one is an intermediate in the synthesis of Sitagliptin Triazecine Analog (S491015). Sitagliptin Triazecine Analog is related to the family of Sitagliptin compounds which has recently been approved for the therapy of type II diabetes. |
|
|